FDA Pulls Emergency Plug on Pfizer, Moderna, and Novavax COVID Shots
Published Date: 10/2/2025
Notice
Summary
The FDA is ending the emergency use permissions for Pfizer, Moderna, and Novavax COVID-19 vaccines. This means these vaccines are no longer authorized under emergency rules, signaling a shift as the pandemic changes. People and healthcare providers should note this update, but it doesn’t mean the vaccines are unsafe or unavailable through regular approvals.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
EUA Revoked for Three COVID-19 Vaccines
The FDA revoked the Emergency Use Authorizations (EUAs) for Pfizer‑BioNTech COVID‑19 Vaccine, Moderna COVID‑19 Vaccine, and Novavax COVID‑19 Vaccine, Adjuvanted, so these products are no longer authorized under emergency rules. The notice says this change does not mean the vaccines are unsafe and that they may still be available through regular (non‑emergency) approval pathways.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-19271, 60-Day Notice of Proposed Information Collection: Standards for Success Reporting
HUD wants to update how they collect info about success stories from programs they fund. This affects organizations that report to HUD, asking them to share clearer, easier-to-understand results. They’re asking for public feedback over the next 60 days before making changes, aiming to keep things simple without adding extra costs or paperwork.
Next: 2025-19273, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their money and property in the U.S. are frozen. Americans can’t do business with these folks anymore, so watch out for blocked transactions. This move helps keep bad actors from using the U.S. financial system, effective immediately.